Living with systemic lupus erythematosus (SLE) can be a constant battle against inflammation. New data suggests that adding telitacicept to standard therapy might help patients see better results. Specifically, the study looked at the SRI-4 response, which is a way to measure how well a patient's condition improves over time.
In the study, adults with active SLE and lupus nephritis received 160 mg of telitacicept along with their usual medications. The results showed that this combination significantly increased the response rate compared to a placebo over a period of 48 to 52 weeks. While the treatment showed promise for managing symptoms, it did result in a slight increase in the number of reported adverse events.
It is important to note that while the primary results are encouraging, the evidence for other outcomes is still uncertain. The study also did not establish long-term safety or how this drug compares to other specific treatments. Because the evidence for some outcomes is still limited, patients should talk to their doctors to see if this option fits their specific needs.
